Background. We evaluated the efficacy of intravenous immunoglobulin (IVIG) therapy in patients with pure red cell aplasia (PRCA) related to human parvovirus B19 (HPV-B19) infection.
Pure red cell aplasia (PRCA), first characterized by Kaznelson in 1922 [1] , is defined by the absence of mature erythroid precursors in otherwise normocellular bone marrow [2] . PRCA may present as a congenital disorder or an acquired syndrome. It may occur during lymphoproliferative disorders; other neoplastic disorders, including thymoma; autoimmune diseases such as systemic lupus erythematosus (SLE); pregnancy; or treatments including recombinant human erythropoietin and ABO-incompatible hematopoietic stem cell transplant. PRCA may also be associated with myelodysplasia or chronic human parvovirus B19 (HPV-B19) infection.
HPV-B19, a small Parvoviridae DNA virus, is an important pathogen in humans. Primary infection is asymptomatic in most cases. Acute infection produces fifth disease (erythema infectiosum) in immunologically competent individuals, transient aplastic crisis in patients with chronic hemolysis, and PRCA in the immunologically incompetent host [3] . Fetal infection can lead to hydrops fetalis. The target cell is the erythroid progenitor in bone marrow. Persisting infection is usually secondary to insufficient neutralizing antibody synthesis.
The reported prevalence of HPV-B19 immunoglobulin G (IgG) antibodies ranges from 50% to 75% in the general population [4] . Intravenous immunoglobulin (IVIG), which contains a large amount of anti-HPV-B19 IgG, is the treatment of choice for HPV-B19 PRCA. Since the first report of IVIG treatment, in 1989 [5] , it has been used to treat severe anemia secondary to chronic HPV-B19 infection in immunocompromised patients [6] . However, the disease is so rare that controlled studies cannot be performed, and the rationale for the use of IVIG in HPV-B19 PRCA is based on small retrospective case studies and case reports [7] [8] [9] [10] [11] [12] .
We retrospectively reviewed all cases of IVIG treatment for HPV-B19 PRCA in Assistance Publique-Hôpitaux de Paris (AP-HP) hospitals between January 2000 and December 2005 to better evaluate the efficacy of IVIG treatment for this condition. In addition, we reviewed all cases of IVIG treatment for HPV-B19 PRCA published to date in the literature.
METHODS

Patient Selection
The expert group of the AP-HP is a scientific board of physicians and pharmacists that convenes to examine IVIG indications and provide treatment recommendations. With the help of the expert group, we obtained an exhaustive list of patients who had received IVIG between January 2000 and December 2005 in the AP-HP for presumed HPV-B19 PRCA.
We obtained patient records after e-mailing medical practitioners in France who used IVIG for presumed HPV-B19 PRCA. PRCA was defined by the absence of mature erythroid precursors in otherwise normocellular bone marrow (or deep reticulocytopenia in the absence of other possible causes). Standard qualitative whole-blood polymerase chain reaction (PCR) amplification was used for HPV-B19 detection. We excluded patients without PRCA and/or who did not fulfill the criteria for HPV-B19 infection (ie, absence of or negative PCR test results for HPV-B19 for blood and/or bone-marrow aspiration). We considered the possibility of other causes of PRCA in these patients, such as autoimmune and/or drug-induced PRCA.
Patient Data
A standardized form was used to extract data on personal and medical background (age; sex; ethnicity; employment; physician name; immunocompromised status, including human immunodeficiency virus [HIV] infection; solid-organ transplant; autologous or allogenic hematopoietic stem cell transplant; treatments), PRCA diagnosis (ie, clinical setting, hemography, reticulocytes, bone-marrow aspiration), HPV-B19 infection (ie, consistent symptoms, serology, blood and/or bone-marrow PCR), treatment modalities (IVIG dose, duration, and number of courses; immunosuppressive therapy discontinuation), side effects, and patient outcomes. Correction of hemoglobin level was defined as hemoglobin level >12 g/dL or a return to the level before PRCA diagnosis or relapse with new-onset anemia related to PRCA after correction of hemoglobin level.
Endpoints
The primary endpoint was correction of hemoglobin level at 12 months after the first IVIG course. Secondary endpoints were recurrence of PRCA, remission length, sustained corrected hemoglobin level at 6 months after the last IVIG course, time to correction of hemoglobin level and reticulocytosis (ie, >100 × 10 9 /L reticulocytes), negative HPV-B19 PCR test result in blood and/or bone marrow, side effects, and death.
Literature Review
We reviewed the literature for cases of HPV-B19 PRCA treated with IVIG by searching for articles published in Medline from January 1984 to March 2012 with the following MeSH (medical subject headings) keywords tested 2 by 2: pure red cell aplasia, human parvovirus B19, and intravenous immunoglobulin. In total, 198 articles were identified, and 125 were excluded by reviewing the title or text. We reviewed the reference lists of identified publications for other publications. 
Ethical Considerations
This survey was conducted in compliance with the protocol of Good Clinical Practices and Declaration of Helsinki principles. In accordance with French law, formal approval from an ethical committee was not required for this kind of project.
RESULTS
Patients Receiving IVIG for Presumed HPV-B19 Infection
We obtained medical files for 36 patients for whom pharmacists had information about receipt of IVIG for HPV-B19 PRCA. Only 22 patients fulfilled the diagnosis criteria for PRCA, and only 10 had documented HPV-B19 infection as defined in the Methods section ( Figure 1 ). The 12 other patients had negative HPV-B19 PCR results in blood; 2 had undergone bone-marrow HPV-B19 PCR, with negative results.
Characteristics of Patients With HPV B19 PRCA
In our series, all but 1 patient with HVP-B19 PRCA showed previously identified immunodeficiency, due to immunosuppressive treatment (7 patients), low-dose corticosteroid treatment, or AIDS (1 each) ( Table 1) . Five patients had experienced increased immunosuppression within the 4 months before HPV-B19 PRCA diagnosis (kidney transplant in 3, autologous hematopoietic stem cell transplant in 1, and chemotherapy for multiple myeloma in 1). Only 1 patient Table 2 ). With the exception of 2 patients, all had a history of immune deficiency, mainly solid-organ transplant (47%), HIV infection (30%), or hematologic disorder (14%). The underlying immunosuppressive conditions changed over the years: AIDS was predominant before 2004 (52.5% of patients), and solid-organ or stem cell transplant was most frequent after 2005 (64% and 14% of patients, respectively).
Anemia
In our series, PRCA occurred after a mean of 29.1 ± 44.9 months of immunosuppressive therapy. Two patients experienced lipothymia and 1 patient had chest pain related to coronary insufficiency. All patients had severe anemia (mean hemoglobin level, 5.9 ± 1.9 g/dL [range, 1.8-7.9 g/dL]) and 8 of 10 had low reticulocyte count (<8 × 10 
HPV-B19 Infection
Six of our 10 patients presented symptoms consistent with HPV-B19 infection (Table 1) . One patient with SLE had myocarditis with altered left ventricular ejection fraction (35%). When performed, IgM anti-HPV-B19 test results were always negative, but HPV-B19 PCR results for blood and bone marrow were positive for 3 of 6 and 7 of 7 patients, respectively. In 1 patient, peripheral-blood HPV-B19 PCR results were initially negative and became positive 13 days after the PRCA diagnosis. No patient had suggestive HPV-B19 bone-marrow findings (giant proerythroblasts or vacuoles in erythroblast precursors). Among the 133 patients, the mean time to PRCA diagnosis after the initiation of immunosuppression was 18.3 ± 38.0 months; 34 patients (26%) had symptomatic HPV-B19 infection: temperature >38°C (n = 21); headache, arthralgia, and/or myalgia (n = 11); skin rash (n = 8); acute renal failure (n = 5); graft dysfunction (n = 4); sore throat, stridor, pneumonia, and hepatitis (1 fatal case; n = 2 cases each); and encephalitis, central nervous system vasculitis, myocarditis, pleural effusion, and microangiopathy (n = 1 each). At disease onset, 46%, 71%, and 49% of patients had anti-HPV-B19 IgM antibodies, positive peripheral-blood and/or bone-marrow HPV-B19 PCR results, and suggestive HPV-B19 bone-marrow findings, respectively. Among 72 patients with positive peripheral-blood and/or bone-marrow HPV-B19 PCR results and available serologic data, only 30 (42%) had detectable anti-HPV-B19 IgM antibodies.
Treatment
Eight of our 10 patients required blood transfusion before IVIG infusion (mean, 4.1 ± 3.0 [range, 2-8] erythrocyte packs per patient). Immunosuppressive therapy was decreased in 3 solid-organ transplant recipients, and additional non-IVIG treatments were prescribed in 4 patients (erythropoietin injection in 3 patients, cobalamin and folic acid in 1 patient). IVIG was administered at a mean of 1.3 ± 0.54 (range, 0.25-2) g/kg/ course for 2.53 ± 1.60 (range, 1-6) days and 2.4 ± 1.8 (range, 1-7) courses. Seven patients received Tegeline (LFB Biotechnologies) and 3 Octagam (Octapharma). None received IVIG maintenance treatment. Overall, the 133 patients received a mean of 2.8 ± 9.1 IVIG courses at 2.3 ± 1.3 g/kg for the first course, for 4.9 ± 3.3 days (Table 3) . Immunosuppression was reduced in 38% of patients (42/109) (discontinuation of immunosuppressants in 32% and highly active antiretroviral therapy introduction in 6%). In all, (7) 2 (20) 8 (6) Systemic autoimmune and/or inflammatory disease 7 (5) 1 (10) 6 (5) Hematopoietic stem cell transplant 10 (7) 2 (20) 22% of patients with solid-organ transplant were switched from tacrolimus to cyclosporine; IVIG therapy was maintained at 0.4-1 g/kg every 4 weeks for 16 patients (12%).
Response to Treatment
In our series, all patients were alive and all but 1 showed normal hemoglobin level at 12 months (Table 1 ). The only nonresponder ( patient 10) had underlying myelodysplasia and the condition improved with recombinant erythropoietin. In 1 patient, low-dose IVIG for transplant rejection (0.25 g/kg) failed to cure PRCA, although it reduced the frequency of erythrocyte infusions from once a month to once every 2 months. Follow-up data for blood HPV-B19 PCR were available for 7 patients and results became negative within a mean of 97 days (range, 35-159 days) for 5. Among the 2 patients with persistent positive HPV-B19 PCR results for blood, 1 showed normalized hemoglobin concentration. In 93% of the 133 patients, hemoglobin level was normalized after the first IVIG course after a mean of 1.7 ± 1.6 months; 34% patients showed relapse, at a mean of 4.3 ± 2.71 months. For 47% of patients with available 12-month followup data (45/96), hemoglobin level was corrected 12 months after the first IVIG course. HPV-B19 PCR results became negative for 30.5% cases. In total, 14 patients died during followup (AIDS-related opportunistic infection, Kaposi sarcoma, or lymphoma [n = 7]; HPV-B19 infection-induced fibrosing cholestatic hepatitis, hepatic tumor, sarcoidosis with severe thrombocytopenia, and cerebral hemorrhage [n = 1 each]; or unknown [n = 4]).
At 12 months, IVIG responders differed significantly from nonresponders by sex (51% vs 76% males, P = .025), HIV infection (22% vs 45%, P = .03) and positivity for anti-HPV-B19 IgM antibodies at diagnosis (56% vs 29%, P = .03) ( Table 4) .
On multivariate analysis, HIV infection was significantly associated with death (OR, 5.61 [95% CI, 1.34-23.5], P = .02), but 12-month response to IVIG was associated with survival (OR, 0.11 [95% CI, .01-.94], P = .04). Survival was significantly enhanced for responders (Figure 2 ).
Tolerance to IVIG Treatment
We noted adverse events related to IVIG treatment in 5 of our 10 patients. Two who received Octagam showed acute renal failure but did not need dialysis. Pulmonary edema developed in 2 other patients, including 1 with a history of surgically cured interauricular communication, pulmonary hypertension, and cardiotoxic chemotherapy and 1 with evidence of myocarditis. One patient experienced transient hemolysis. In 1 patient, fever, chills, and rash resolved after the IVIG infusion rate was decreased. Among the 133 patients, IVIG tolerance was good, and side effects were mentioned for only 18 (13.5%): acute renal failure in 9 (including 6 kidney transplant recipients); fever, rash, and joint pain in 7; and left ventricular failure in 2.
DISCUSSION
We retrospectively reviewed data for a series of 10 patients with HPV-B19 PRCA treated with IVIG from 2000 to 2005 and reviewed 123 additional cases from the literature, for a pooled analysis of 133 patients. Although limited to 10 cases, our series is among the largest to date. One of the explanations for the rarity of HPV-B19 PRCA cases is probably the low incidence of HPV-B19 viremia, reported in 5%-23% of kidney transplant patients [13] and 0.95%-4.5% of AIDS patients [14] . Only 1 of our 10 patients had HIV infection, which is in agreement with the literature: during the last decade, <5% of reported cases of HPV-B19 PRCA treated with IVIG occurred in HIV-infected patients as compared with 30% during the previous decade.
Taken together, our data, combined with data from the literature, indicate that immunologic status (93.2% of immunocompromised patients) is a more sensitive diagnosis clue of HPV-B19 PRCA than clinical manifestations related to HPV-B19 infection, which are lacking in 74% of the cases. In our series, the clinical judgment has poor specificity, because empiric IVIG treatment was performed for final diagnoses other than HPV-B19 PRCA in 72% of cases. Because the efficacy of IVIG infusion in the absence of HPV-B19 PRCA is controversial, IVIG treatment should be started only after confirming the PRCA diagnosis and documenting HPV-B19 infection with positive PCR results.
We confirmed the lack of sensitivity of HPV-B19 IgM serology for HPV-B19 PRCA diagnosis and the good sensitivity of suggestive bone-marrow findings and standard PCR assay in immunocompromised patients (71%-97%, 84%, and 90%-94% in immunocompromised [14, 15] and immunocompetent [16] patients, respectively). However, in our series, HPV-B19 PCR in blood was much less sensitive than bonemarrow PCR and we failed to identify suggestive bonemarrow findings. At 1 year, 9 of our 10 patients and 93% of patients in the literature showed complete remission of HPV-B19 PRCA. These results should encourage the use of IVIG for treating HPV-B19 PRCA in immunocompromised patients, although spontaneous cure of HPV-B19 PRCA occurred in 8% in a series of 98 patients [15] . Interestingly, non-PRCA manifestations associated with HPV-B19 infection such as renal insufficiency [17] , neutropenia or thrombocytopenia [18] , and systemic vasculitis [7, 19] may be alleviated with IVIG treatment.
The optimal schedule of IVIG treatment is not known. Treatment has failed with low or intermediate doses (0.25-1 g/kg) [20] , but we found efficacy in most literature cases with up to 2.3 ± 1.3 g/kg. Thus, these results support the use of at least 2 g/kg of IVIG per course. Because 34% of responders showed relapse within a mean of 4.3 months, subsequent IVIG courses were often needed, with a 12-month success rate of 47%. Interestingly, in patients with severe immune deficiency, particularly in the absence of HPV-B19 IgM antibodies and/or with HIV infection, the prognosis was worse than in others, and additional courses of IVIG might be proposed systematically. Seroconversion [8, [21] [22] [23] , highly active antiretroviral therapy introduction [21, [24] [25] [26] [27] , or a switch from tacrolimus to cyclosporin A [11, 20, 28, 29] , all of which contribute to improved immune status, have been associated with cured HPV-B19 infection and should encourage immune restoration in these patients.
As compared with 10% of patients showing side effects in the literature, 4 of our 10 patients showed intolerance to IVIG. Two cases of acute renal failure occurred with Octagam, whose maltose-based excipient is considered better tolerated than the sucrose contained in Tegeline [30] . This finding underlies the fact that nephrotoxicity of IVIG, a rare complication with an estimated incidence of <1% [31] , depends more on the rate of infusion (1 g/kg/d in each case) than on the stabilizing agent used in the IVIG preparation. Two of our 10 patients experienced pulmonary edema, not a common side effect of IVIG treatment. However, the high rate of IVIG infusion and blood transfusion in patients with anemia and underlying risk factors for cardiomyopathy probably contribute to this type of adverse event. In this setting, myocarditis due to HPV-B19 infection cannot be excluded, as in 5.9% of patients with solid-organ or hematopoietic stem cell transplant [15] , which should lead to caution during fluid infusion and/ or transfusion.
In conclusion, IVIG therapy appears to be effective in the short term in immunocompromised patients with HPV-B19 PRCA. Additional studies are needed to better define the optimal dose and number of IVIG courses, as well as predictive factors of PRCA relapse, for these patients. Figure 2 . Overall survival of patients with human parvovirus B19 pure red cell aplasia by response to intravenous immunoglobulin treatment.
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